Daprodustat related drug information and application prospects

Daprodustat (Daprodustat) is an oral small molecule drug developed by GlaxoSmithKline (GSK). It is mainly used to treat chronic kidney disease combined withanemia. Its research and development background stems from the need to improve the traditional erythropoietin (ESA) treatment model. For a long time, ESA injection preparations have been widely used in clinical practice. However, its administration method is inconvenient, and some patients have insufficient response to exogenous EPO. Coupled with potential cardiovascular risk issues, the development of new oral treatment options has become an urgent clinical direction. Daprostat, a representative drug of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was launched into the global market under this background.

In terms of drug information, daprostat has been approved for marketing in many countries such as Japan and the United States, and has gradually entered the recommended category of clinical guidelines. It is administered orally once daily. This simplicity greatly improves patient compliance and is especially suitable for long-term use in non-dialysis populations. The drug's indications mainly cover dialysis and non-dialysis patients with chronic kidney disease and anemia. It can not only increase hemoglobin levels, but also improve the body's utilization of iron, thereby reducing dependence on exogenous iron.

From the perspective of application prospects, the promotion significance of daprostat lies not only in the efficacy of the drug itself, but also in the innovation of its treatment concept. Stimulating endogenous red blood cell production by simulating the body's hypoxic state is completely different from the traditional method of simply supplementing exogenous EPO, and embodies the trend of "physiological treatment". The potential advantage is that hemoglobin is less volatile and the risk of long-term complications may be reduced. In addition, daprostat has shown applicability in patients with different stages of chronic kidney disease, providing new possibilities for full-course anemia management in the future.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat